|
1
|
- Daniel Getman, Ph.D.
- Vice-President, Pfizer Global Research and Development
- Director, St Louis Laboratories
- daniel.p.getman@pfizer.com
|
|
2
|
|
|
3
|
- “We intend to make our
internal capability even more effective by tapping into the best
scientific capability outside of our walls - wherever it exists. That’s
why we are reaching out to scientists around the world.”
- - Jeff Kindler
- Pfizer Chairman & CEO
|
|
4
|
|
|
5
|
|
|
6
|
|
|
7
|
- 3 Stages
- Stage 1: Non-Confidential
Technical Evaluation
- Stage 2: Feasibility Study
- Stage 3: Pfizer License &
Option Negotiation
|
|
8
|
|
|
9
|
|
|
10
|
- New targets in disease areas of interest
- Therapeutic drug candidates
- Predictive pharmacology models
- in vitro and in vivo
- Human cell-based assays (pharmacology and toxicology)
- Diagnostics
- Disease-characterizing diagnostics, especially those relevant to the
risk of disease progression
- Pharmacologically-relevant biomarkers
- Development enablers
- Platform technologies
|
Notes
